Karl Donn is currently Senior Vice President, Drug Development at Parion Sciences in Durham, North Carolina. He led the drug discovery program that resulted in the selection of idrevloride as a potent and durable epithelial sodium channel blocker for inhaled delivery to patients with muco-obstructive pulmonary diseases. He continues to lead the development of Idrevloride Inhalation Solution through Phase 3 clinical trials for primary ciliary dyskinesia. He also leads early development respiratory programs for other pulmonary diseases at Parion. Karl has over 45 years of drug development experience in both small and large pharmaceutical companies. Prior to joining Parion, he was the VP, Global Project & Portfolio Management at GlaxoSmithKline where he developed and implemented an industry-leading R&D-wide project management organization that spanned all therapeutic areas at all R&D centers in Europe and North America. He led several project teams, including Cialis®, Zomig® and Avodart®. Prior to his project leadership roles, Karl created and led the Clinical Pharmacokinetics / Pharmacodynamics department and provided PK/PD expertise to several projects including Zantac®, Ceftin®, Imitrex®, Ultiva®, Epivir®, Wellbutrin®, and Cerebyx®. Karl earned a BS in Pharmacy from SUNY at Buffalo, and a MS and PhD from UNC-Chapel Hill School of Pharmacy. He completed a residency in clinical pharmacy at Moses Cone Hospital and a Fellowship in Clinical Drug Research/Drug Development at Burroughs Wellcome Company. He serves on the National Industry Advisory Council for the State University of New York at Buffalo and was recognized by UNC-Chapel Hill School of Pharmacy with their distinguished alumnus award.